Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
1.
Indian J Pediatr ; 2003 Jun; 70(6): 485-8
Article in English | IMSEAR | ID: sea-84128

ABSTRACT

Pertussis still continues to cause significant morbidity and mortality worldwide. Because of the high reactogenicity of whole cell pertussis vaccine, it had evoked public controversy in several countries. In 1970 Japan abandoned use of whole cell pertussis vaccine and mounted efforts to develop better vaccine. To date, nearly 24 acellular pertussis vaccines have been developed, using different number and quantity of components. No acellular vaccine is most or least immunogenic with respect to all included antigens. Vaccine efficacy and duration of immunity is comparable with whole cell pertussis vaccine. The adverse events are two thirds less compared to whole cell vaccine.


Subject(s)
Clinical Trials as Topic , Cost-Benefit Analysis , Diphtheria-Tetanus-Pertussis Vaccine/administration & dosage , Diphtheria-Tetanus-acellular Pertussis Vaccines/administration & dosage , Drug Therapy, Combination , Humans , Immunization Schedule , Pertussis Vaccine/administration & dosage , Whooping Cough/economics
SELECTION OF CITATIONS
SEARCH DETAIL